Ignite Creation Date:
2024-05-06 @ 1:15 AM
Last Modification Date:
2024-10-26 @ 11:01 AM
Study NCT ID:
NCT01767389
Status:
COMPLETED
Last Update Posted:
2014-08-04
First Post:
2013-01-04
Brief Title:
Glucagon-like Peptide GLP Utilization and Safety
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Glucagon-like Peptide-1 GLP-1 Agonists Treatment Utilization Patterns and Risk of Acute Pancreatitis
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the utilization patterns adherence source of the index antidiabetic agent ADA and treatment modification of the marketed glucagon-like peptide-1 GLP-1 receptor agonists exenatide and liraglutide dipeptidyl-peptidase-4 DPP-4 inhibitors sitagliptin saxagliptin and linagliptin and other ADAs and the incidence rate of acute pancreatitis among the users of these GLP-1 receptor agonists and users of DPP-4 inhibitors separately in comparison to other ADAs
The proposed study will help in understanding the treatment utilization patterns and the incidence rate of acute pancreatitis among users of the marketed GLP-1 receptor agonists This study differs from previous observational studies by including both exenatide and liraglutide and follow-up time is expected to be longer in the current study 2005 - 2011
This study will be a retrospective cohort study conducted in the Truven Thomson Reuters commercial health insurance database from 2005-2011
The proposed study will help in understanding the treatment utilization patterns and the incidence rate of acute pancreatitis among users of the marketed GLP-1 receptor agonists This study differs from previous observational studies by including both exenatide and liraglutide and follow-up time is expected to be longer in the current study 2005 - 2011
This study will be a retrospective cohort study conducted in the Truven Thomson Reuters commercial health insurance database from 2005-2011
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| WEUSKOP6477 | OTHER | GSK | None |